Hong Kong’s Medical Device Regulation Gets Major Upgrade: Clearer, More Granular Market Access Requirements - Wiselink Group-A More Controllable, Stable, and Future-Oriented Material Direction

Home > News Center > Hong Kong’s Medical Device Regulation Gets Major Upgrade: Clearer, More Granular Market Access Requirements

Hong Kong’s Medical Device Regulation Gets Major Upgrade: Clearer, More Granular Market Access Requirements

Time：2026-08-04 11:28:49

The Medical Devices Division of the Health Department of the Hong Kong Special Administrative Region has released the newly revised versions of Guidance Document GN-02 Guidance on Listing of Class I/III/IV General Medical Devices and GN-06 Guidance on Listing of Class B/C/D In Vitro Diagnostic Medical Devices, which officially took effect on July 31, 2026. As core operational documents governing Hong Kong’s medical device administrative regime, the revisions cover key dimensions including anti-bribery compliance, Hospital Authority procurement, software and AI medical device supervision, and will exert direct compliance impacts on all enterprises manufacturing medium-to-high-risk medical devices seeking market access in Hong Kong.

原

文

链

接

https://www.mdd.gov.hk/tc/whats-new/mdacs-activities/index-id-2367.html

一、Continuous Refinement of the Regulatory Framework

Hong Kong’s medical device administrative system (formerly the medical instrument administrative system) has undergone accelerated iterations in recent years. In 2025, uniform terminology shifting from "medical instruments" to "medical devices" was completed alongside the renaming of the corresponding regulatory department. Two rounds of rule upgrades were rolled out in 2026: core clause revisions on June 12, followed by detailed optimizations effective July 31. The overall regulatory framework is moving steadily toward international alignment and granular oversight.

The updated GN-02 and GN-06 guidelines serve as the foundational operational reference for filing Class II, III, IV general medical devices and Class B, C, D in vitro diagnostic medical devices into the Medical Device List. They govern the full lifecycle of listing applications, reviews and appeals, making them mandatory compliance reading for enterprises looking to enter the Hong Kong market.

二、Core Highlights of This Round of Revisions

（一）Standalone Anti-Bribery Section Introduced for the First Time, Drawing Clear Compliance Red Lines

A new Section 7 titled "Compliance with the Prevention of Bribery Ordinance" has been added as an independent chapter for the first time. Applicants, their employees and agents are prohibited from offering any advantage as defined under the Prevention of Bribery Ordinance (Cap. 201 of Hong Kong Laws) to any government officer during listing applications or all official interactions with government departments.This means Hong Kong’s medical device regulator has strengthened integrity compliance requirements starting at the market access stage. Enterprises must integrate anti-bribery clauses into their internal compliance systems for Hong Kong operations, covering all staff liaising with government authorities.

（二）New Special Rules for Hospital Authority Procurement to Complete Traceability Chains

A new Section 9 "Medical Devices Procured by the Hospital Authority" has been incorporated. A corresponding disclosure obligation has been added to item E003 of application form MD101: upon submission of an application, enterprises must declare all Hospital Authority (HA) procurement records of the device generated in the preceding 12 months, including purchase order numbers, order dates and supplier names.

After the regulator acknowledges receipt of an application, applicants may proactively update new HA procurement records via the Medical Device Information System (MDIS) if additional HA purchases of the device occur subsequently.

Enterprises focusing on public hospital sales should take particular note: regulators have linked market access and procurement data to enable full traceability, and retention and disclosure of procurement records have become standard compliance requirements.

（三）Stricter Oversight for Software and AI Medical Devices with Defined Market Access Criteria

Two new core technical reference documents are referenced in the revised guidelines：TR-007 Medical Device Software and Cybersecurity、TR-008 Artificial Intelligence Medical Devices

Corresponding upgrades to application dossier requirements apply:：Standalone Medical Devices as Software (SaMD) applicants must submit complete documentation covering software verification & validation, version control, traceability and cybersecurity management in line with TR-007.Manufacturers of AI medical devices are required to compile dedicated technical dossiers complying with TR-008.This reform aligns Hong Kong with global regulatory trends for digital medical devices. Previously vague entry requirements for software and AI-based products are now formalized into clear standards, requiring relevant enterprises to establish structured technical documentation systems in advance.

（四）Refined Standards for Documentation and Translation with Clear Material Specifications

The July 31 revisions optimized Sections 8.3 and 8.4 governing document formalities：

All application materials may only be submitted in Simplified Chinese, Traditional Chinese or English. Documents in other languages must be accompanied by consistent Chinese or English translations matching the original text word-for-word.
Three valid pathways to verify translation accuracy are specified: supporting sales approval certificates issued by regulatory authorities, translations completed by ISO 17100 (or equivalent) certified translation bodies, or notarized translator declarations.

Regulators also restated that electronic certificates bearing verifiable digital signatures from issuing authorities may be submitted electronically without hard copies, though the department reserves the right to verify document authenticity and request certified hard copy duplicates when necessary.

（五）Streamlined Application and Appeal Processes with Greater Transparency

Fixed review timelines：Standard listing applications take 12 weeks to process, counted from the date complete applications and all supporting evidence are received. Failure to submit supplementary materials within required deadlines will result in automatic termination of the application.

Tightened appeal rules：Parties dissatisfied with rejection, conditional approval or device de-listing decisions must file an appeal within 14 working days of receiving the ruling; late submissions will not be accepted. Appeal outcomes will be issued within 4 weeks, and rulings from the Medical Devices Administrative Appeal Board are final and binding.

Auto-enrolment for expedited review: All applications are automatically enrolled in the Expedited Review Scheme by default. Products holding valid marketing approvals from two or more major jurisdictions (China NMPA, US FDA, EU MDR/MDD, Australia TGA, etc.) qualify for the simplified pathway; applicants must manually opt out if they wish to forgo expedited processing.

三、Compliance Action Recommendations for Enterprises

In response to the latest revisions, relevant enterprises are advised to adjust internal workflows as follows:

Upgrade documentation systems：Cross-check existing application dossiers against the new guidelines. Manufacturers of software and AI medical devices should promptly compile dedicated technical files meeting TR-007 and TR-008 requirements. For ongoing in-process applications, liaise with local representatives immediately to confirm if supplementary materials are needed.

Organize procurement records：Enterprises supplying Hong Kong public hospitals should collate all HA purchase orders from the past 12 months to guarantee accurate, traceable disclosure data.

Standardize document translation：Source technical certificates and files written in non-Chinese/non-English languages from ISO 17100-certified translation providers well in advance, allocating sufficient lead time for translation and notarization to avoid review delays.

Leverage expedited review channels：Products holding multiple mainstream international regulatory approvals can take advantage of the auto-enabled simplified review scheme to drastically shorten Hong Kong market launch timelines.

四、Conclusion

As a critical transit hub for medical device manufacturers expanding into Southeast Asia, Hong Kong’s continuously evolving regulatory rules raise market access thresholds while delivering clearer, more stable market expectations for fully compliant enterprises. For further professional consultation, contact Wiselink.

Previous：Confirmed! Distributors Are No Longer Allowed to Apply for UDI-DI Independently Next：FDA Medical Device User Fees Rise Across the Board – Master Timelines to Control Budgets

Fill Form

Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.